Champions Oncology (CSBR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
CSBR dips 1.9% to $4.70, a 52-week low, 4 down days in a row. Closed at $4.70, -1.88% vs the prior close of $4.79. Day range $4.70–$4.84, opened at $4.84.
CSBR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CSBR dips 1.9% to $4.70, a 52-week low, 4 down days in a row
- Closed at $4.70, -1.88% vs the prior close of $4.79. Day range $4.70–$4.84, opened at $4.84.
- Volume was 1.84K shares, 0.2x its 50-day average of 11.32K — lighter than usual.
- Price is -6.1% vs its 50-day average ($5.00) and -19.6% vs its 200-day average ($5.85).
- 52-week range $4.59–$8.31; today's close sits at 3% of that range, 43.4% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — CSBR dips 0.4% to $4.79, 3 down days in a row
- Closed at $4.79, -0.42% vs the prior close of $4.81. Day range $4.75–$4.86, opened at $4.80.
- Volume was 9.90K shares, 0.9x its 50-day average of 11.42K.
- Price is -4.4% vs its 50-day average ($5.01) and -18.2% vs its 200-day average ($5.86).
- 52-week range $4.59–$8.31; today's close sits at 5% of that range, 42.4% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — CSBR dips 1.8% to $4.81
- Closed at $4.81, -1.84% vs the prior close of $4.90. Day range $4.76–$4.87, opened at $4.76.
- Volume was 3.00K shares, 0.3x its 50-day average of 11.73K — lighter than usual.
- Price is -4.2% vs its 50-day average ($5.02) and -18.0% vs its 200-day average ($5.87).
- 52-week range $4.59–$8.31; today's close sits at 6% of that range, 42.1% below the 52-week high.
Oct 13, 2026 — CSBR dips 1.0% to $4.90
- Closed at $4.90, -1.01% vs the prior close of $4.95. Day range $4.72–$4.93, opened at $4.81.
- Volume was 3.10K shares, 0.3x its 50-day average of 11.73K — lighter than usual.
- Price is -2.7% vs its 50-day average ($5.04) and -16.6% vs its 200-day average ($5.88).
- 52-week range $4.59–$8.31; today's close sits at 8% of that range, 41.0% below the 52-week high.
Oct 12, 2026 — CSBR rises 2.3% to $4.95
- Closed at $4.95, +2.27% vs the prior close of $4.84. Day range $4.82–$4.95, opened at $4.84.
- Volume was 11.40K shares, 1.0x its 50-day average of 11.54K.
- Price is -2.0% vs its 50-day average ($5.05) and -15.9% vs its 200-day average ($5.89).
- 52-week range $4.59–$8.31; today's close sits at 10% of that range, 40.4% below the 52-week high.
Oct 9, 2026 — CSBR dips 2.8% to $4.84
- Closed at $4.84, -2.81% vs the prior close of $4.98. Day range $4.84–$4.99, opened at $4.91.
- Volume was 1.90K shares, 0.2x its 50-day average of 11.83K — lighter than usual.
- Price is -4.4% vs its 50-day average ($5.06) and -17.9% vs its 200-day average ($5.90).
- 52-week range $4.59–$8.31; today's close sits at 7% of that range, 41.8% below the 52-week high.
Oct 8, 2026 — CSBR rises 2.0% to $4.98
- Closed at $4.98, +2.05% vs the prior close of $4.88. Day range $4.88–$5.00, opened at $4.88.
- Volume was 2.80K shares, 0.2x its 50-day average of 12.00K — lighter than usual.
- Price is -1.8% vs its 50-day average ($5.07) and -15.7% vs its 200-day average ($5.91).
- 52-week range $4.59–$8.31; today's close sits at 10% of that range, 40.1% below the 52-week high.
Oct 7, 2026 — CSBR dips 2.6% to $4.88 on 2.3x normal volume
- Closed at $4.88, -2.59% vs the prior close of $5.01. Day range $4.80–$5.00, opened at $4.93.
- Volume was 27.20K shares, 2.3x its 50-day average of 12.08K — unusually heavy trading.
- Price is -3.9% vs its 50-day average ($5.08) and -17.6% vs its 200-day average ($5.92).
- 52-week range $4.59–$8.31; today's close sits at 8% of that range, 41.3% below the 52-week high.
Oct 6, 2026 — CSBR rises 0.8% to $5.01, 3 up days in a row
- Closed at $5.01, +0.80% vs the prior close of $4.97. Day range $4.85–$5.01, opened at $4.92.
- Volume was 16.00K shares, 1.3x its 50-day average of 11.92K.
- Price is -1.6% vs its 50-day average ($5.09) and -15.6% vs its 200-day average ($5.93).
- 52-week range $4.59–$8.31; today's close sits at 11% of that range, 39.7% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — CSBR rises 0.6% to $4.97
- Closed at $4.97, +0.61% vs the prior close of $4.94. Day range $4.94–$5.18, opened at $4.96.
- Volume was 11.10K shares, 0.9x its 50-day average of 11.93K.
- Price is -2.8% vs its 50-day average ($5.11) and -16.3% vs its 200-day average ($5.94).
- 52-week range $4.59–$8.31; today's close sits at 10% of that range, 40.2% below the 52-week high.
Oct 2, 2026 — CSBR rises 1.2% to $4.94
- Closed at $4.94, +1.23% vs the prior close of $4.88. Day range $4.92–$5.07, opened at $5.04.
- Volume was 3.60K shares, 0.3x its 50-day average of 11.88K — lighter than usual.
- Price is -3.8% vs its 50-day average ($5.14) and -17.0% vs its 200-day average ($5.95).
- 52-week range $4.59–$8.31; today's close sits at 9% of that range, 40.6% below the 52-week high.
CSBR latest news & SEC filings
Every SEC filing by or about CSBR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ackerman Joel converted options/RSUs into 69,794 shares at $1.60 (≈$111.67K) on Oct 15, 2026; now holds 1,126,333
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jul 31, 2026:
- Revenue: $15.23M (prior year $13.99M) (+8.8% vs Jul 31, 2025)
- Net income: -$426.00K (prior year -$466.00K) (loss narrowed vs Jul 31, 2025)
- Diluted EPS: -$0.03 (prior year -$0.03) ( vs Jul 31, 2025)
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 28, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 28, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Jul 27, 2026 · Form 10-K — Annual report
Annual report (audited full-year financial statements and business review)
Fiscal year ended Apr 30, 2026:
- Revenue: $59.42M (prior year $56.94M) (+4.4% vs Apr 30, 2025)
- Net income: -$1.18M (prior year $4.70M) (loss widened vs Apr 30, 2025)
- Diluted EPS: -$0.08 (prior year $0.33) (loss widened vs Apr 30, 2025)
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade CSBR
- Last results release: Sep 10, 2026 (8-K Item 2.02). Previous ones: Jul 27, 2026, Mar 12, 2026, Dec 15, 2025. Based on that rhythm, the next report is likely around Dec 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.83% (largest 5.1%).
- Liquidity: about 9.23K shares (≈$43.39K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $4.70 vs a range of $4.59–$8.31 (3% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 16, 2026; 10-Q Sep 11, 2026; 8-K Sep 10, 2026.
- Share count: 13.92M shares outstanding (Sep 9, 2026), +0.9% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CSBR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.84 | 4.84 | 4.70 | 4.70 | 1.84K |
| Oct 15, 2026 | 4.80 | 4.86 | 4.75 | 4.79 | 9.90K |
| Oct 14, 2026 | 4.76 | 4.87 | 4.76 | 4.81 | 3.00K |
| Oct 13, 2026 | 4.81 | 4.93 | 4.72 | 4.90 | 3.10K |
| Oct 12, 2026 | 4.84 | 4.95 | 4.82 | 4.95 | 11.40K |
| Oct 9, 2026 | 4.91 | 4.99 | 4.84 | 4.84 | 1.90K |
| Oct 8, 2026 | 4.88 | 5.00 | 4.88 | 4.98 | 2.80K |
| Oct 7, 2026 | 4.93 | 5.00 | 4.80 | 4.88 | 27.20K |
| Oct 6, 2026 | 4.92 | 5.01 | 4.85 | 5.01 | 16.00K |
| Oct 5, 2026 | 4.96 | 5.18 | 4.94 | 4.97 | 11.10K |
| Oct 2, 2026 | 5.04 | 5.07 | 4.92 | 4.94 | 3.60K |
| Oct 1, 2026 | 4.97 | 5.04 | 4.86 | 4.88 | 2.40K |
| Sep 30, 2026 | 4.86 | 5.00 | 4.80 | 5.00 | 35.20K |
| Sep 29, 2026 | 4.97 | 5.04 | 4.79 | 4.79 | 15.10K |
| Sep 28, 2026 | 4.90 | 4.98 | 4.89 | 4.93 | 4.40K |
| Sep 25, 2026 | 4.81 | 4.96 | 4.80 | 4.90 | 8.80K |
| Sep 24, 2026 | 4.94 | 4.95 | 4.94 | 4.95 | 3.70K |
| Sep 23, 2026 | 5.10 | 5.31 | 5.02 | 5.02 | 1.50K |
| Sep 22, 2026 | 4.94 | 5.29 | 4.94 | 5.29 | 11.30K |
| Sep 21, 2026 | 5.30 | 5.30 | 5.08 | 5.26 | 10.40K |
About Champions Oncology
Champions Oncology (CSBR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in BALTIMORE, MD. State of incorporation: DE. Fiscal year ends April 30. SEC CIK 771856.
CSBR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Joel Ackerman | Director | Nov 7, 2025 |
| Robert Lawrence Brainin | Director | Jan 30, 2026 |
| Philip P. Breitfeld | Director | Nov 7, 2025 |
| Daniel Newman Mendelson | Director | Nov 7, 2025 |
| David Sidransky | Director | Nov 7, 2025 |
| Scott R Tobin | Director | Nov 7, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
CSBR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Apr 30, 2026 | $59.42M | $-1.18M | -0.08 | $-4.47M |
| Apr 30, 2025 | $56.94M | $4.70M | 0.33 | $7.39M |
| Apr 30, 2024 | $50.16M | $-7.28M | -0.54 | $-6.14M |
| Apr 30, 2023 | $53.87M | $-5.33M | -0.39 | $3.97M |
| Apr 30, 2022 | $49.11M | $548.00K | 0.04 | $6.50M |
Latest balance sheet: total assets $33.29M, total liabilities $28.83M, cash $4.36M (as of Jul 31, 2026).
CSBR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 10, 2026 | 8-K Item 2.02 (results) | $5.10 |
| Jul 27, 2026 | 8-K Item 2.02 (results) | $6.06 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $5.74 |
| Dec 15, 2025 | 8-K Item 2.02 (results) | $7.80 |
| Sep 15, 2025 | 8-K Item 2.02 (results) | $8.30 |
| Jul 23, 2025 | 8-K Item 2.02 (results) | $7.75 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $9.79 |
| Dec 11, 2024 | 8-K Item 2.02 (results) | $5.84 |
| Sep 11, 2024 | 8-K Item 2.02 (results) | — |
| Jul 18, 2024 | 8-K Item 2.02 (results) | — |
| Mar 12, 2024 | 8-K Item 2.02 (results) | — |
| Dec 12, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CSBR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.